Abstract
The cannabinoid-1 receptor (CB1) plays a critical role in a number of biological processes including nutrient intake, addiction and anxiety-related behaviour. Numerous studies have shown that expression of the gene encoding CB1 (CNR1) is highly dynamic with changes in the tissue specific expression of CNR1 associated with brain homeostasis and disease progression. However, little is known of the mechanisms regulating this dynamic expression. To gain a better understanding of the genomic mechanisms modulating the expression of CNR1 in health and disease we characterised the role of a highly conserved regulatory sequence (ECR1) in CNR1 intron 2 that contained a polymorphism in linkage disequilibrium with disease associated SNPs. We used CRISPR/CAS9 technology to disrupt ECR1 within the mouse genome. Disruption of ECR1 significantly reduced CNR1 expression in the hippocampus but not in the hypothalamus. These mice also displayed an altered sex-specific anxiety-related behavioural profile (open field test), reduced ethanol intake and a reduced hypothermic response following CB1 agonism. However, no significant changes in feeding patterns were detected. These data suggest that, whilst not all of the expression of CNR1 is modulated by ECR1, this highly conserved enhancer is required for appropriate physiological responses to a number of stimuli. The combination of comparative genomics and CRISPR/CAS9 disruption used in our study to determine the functional effects of genetic and epigenetic changes on the activity of tissue-specific regulatory elements at the CNR1 locus represent an important first step in gaining a mechanistic understanding of cannabinoid regulatory pharmacogenetics.
| Original language | English |
|---|---|
| Article number | 104407 |
| Pages (from-to) | 104407 |
| Number of pages | 8 |
| Journal | Psychoneuroendocrinology |
| Volume | 109 |
| Early online date | 13 Aug 2019 |
| DOIs | |
| Publication status | Published - Nov 2019 |
Bibliographical note
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.Funding
All animal experiments were conducted in full accordance with UK Home Office guidelines as stipulated in the Animals in Scientific Research act of 1986. This study was undertaken under a current UK Home Office 5-year project licence (PPL number: P5D8BAA7D) which was subjected to ethical review by the University of Aberdeen ethical review board prior to submission to the Home Office in 2016. Animals were euthanised using UK Home Office approved schedule-1 techniques. 3 EH was funded by Medical Research Scotland ( PhD-719-2013 ) and GW Pharmaceuticals . AMcE was funded by BBSRC project grant ( BB/N017544/1 ). PB and DW are funded by the Scottish Government Rural and Environment Science and Analytical Services Division to the Rowett Institute.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cannabinoid-1 receptor
- CRISPR genome editing
- gene regulation
- tissue specific
- enhancer
- polymorphisms
- ethanol intake
- CB1 agonists
- Win55
- 212-2
- pharmacogenetics
- Ethanol intake
- Pharmacogenetics
- Enhancer
- NICOTINE
- Gene regulation
- Tissue specific
- ENDOCANNABINOID SYSTEM
- Anxiety-related behavior
- Polymorphisms
- HIPPOCAMPUS
- Wln55,212-2
- CB1 RECEPTORS
- HYPOTHALAMUS
Fingerprint
Dive into the research topics of 'Disruption of an enhancer associated with addictive behaviour within the cannabinoid receptor-1 gene suggests a possible role in alcohol intake, cannabinoid response and anxiety-related behaviour'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS